Aciclovir 5% w/w - Sökresultat

amneal pharma australia pty ltd - valaciclovir hydrochloride monohydrate, quantity: 611.7 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of opthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with vaciclor, it is recommended that patients use safer sex practices (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

valaciclovir an 500mg

amneal pharma australia pty ltd - valaciclovir hydrochloride -

Australien - engelska - Department of Health (Therapeutic Goods Administration)

arx-aciclovir aciclovir 800mg tablet blister pack

arrotex pharmaceuticals pty ltd - aciclovir, quantity: 800 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - arx-aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advaned symptomatic hiv disease cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and administration" sections of the approved product information provided as attachment 1.